PubMed · 1987 · 30 citations · 5 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyTumor ImmunologyAntibody ConjugatesAntibody ConjugationAntibody-drug ConjugatesCancer ImmunotherapyAntibody-directed ProdrugsAntibody-drug Conjugate AntibodiesAntibody-drug Conjugate TherapyMonoclonal Antibodies In OncologyRodent Tumor ModelsTumor Suppression MechanismsTumor Targeting Specificity
The human squamous carcinoma-reactive murine monoclonal antibody PF1/D was used to derive a conjugate with the Vinca derivative 4-desacetylvinblastine-3-carboxyhydrazide (PF1/D-DAVLBHYD). This immunoconjugate was shown to be largely aggregate free and there was no loss of immunoreactivity postconjugation. When tested in vivo in a 3-day-established human squamous carcinoma nude mouse xenograft model, the PF1/D-DAVLBHYD conjugate eliminated tumor growth with three injections (days 3, 6, and 9) at 2 mg/kg Vinca content. Significant tumor suppression was also observed with 0.5 mg/kg conjugate doses. In contrast, free PF1/D antibody had minimal antitumor activity and no activity was seen with identical doses of a control non-tumor-binding IgG-DAVLBHYD conjugate. Together, these data demonstrate the specificity of the PF1/D-DAVLBHYD antitumor effects.
5
Demonstration of antibodies against human malignant melanoma by immunofluorescence.
Morton Dl, Malmgren Ra, Holmes Ec et al. · PubMed · 1968 · 388 citations
Life Sciences, Immunology, Oncology +12
Antitumor properties of vindesine-monoclonal antibody conjugates
G. F. Rowland, C.A. Axton, R W Baldwin et al. · Cancer Immunology Immunotherapy · 1985 · 76 citations · Full text
R. Conrad, George J. Cullinan, Koert Gerzon et al. · Journal of Medicinal Chemistry · 1979 · 57 citations
Antigens associated with human squamous cell lung carcinoma defined by murine monoclonal antibodies
Philip Fernsten, K W Pekny, R. Reisfeld et al. · Lung Cancer · 1987 · 29 citations
Medicine, Immunology, Oncology +14